<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/39261/byondis-develops-new-biological-and-chemical-entities-a-proprietary-linker-drug-platform-to-generate-multiple-novel-adcs---what-other-cancers-are-you-planning-to-target-with-syd985---mar.?channelName=Cancer-News" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what other cancers are you planning to target with SYD985 - Mar...

0:03:21

Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what other cancers are you planning to target with SYD985 - Mar...

User Photo

Cancer-News

6 months

18 Views

Share Report Add to 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/39261/byondis-develops-new-biological-and-chemical-entities-a-proprietary-linker-drug-platform-to-generate-multiple-novel-adcs---what-other-cancers-are-you-planning-to-target-with-syd985---mar.?channelName=Cancer-News" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://www.oncologytube.com/videoEmbed/39261/byondis-develops-new-biological-and-chemical-entities-a-proprietary-linker-drug-platform-to-generate-multiple-novel-adcs---what-other-cancers-are-you-planning-to-target-with-syd985---mar.?channelName=Cancer-News"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://www.oncologytube.com/videoEmbed/39261/byondis-develops-new-biological-and-chemical-entities-a-proprietary-linker-drug-platform-to-generate-multiple-novel-adcs---what-other-cancers-are-you-planning-to-target-with-syd985---mar.?channelName=Cancer-News" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://www.oncologytube.com/v/39261?channelName=Cancer-News"><img src="https://www.oncologytube.com/videos/_YPTuniqid_5f49802789df97.69164865.jpg?1598652495">Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what other cancers are you planning to target with SYD985 - Mar...</a>

Link (BBCode):

[url=https://www.oncologytube.com/v/39261?channelName=Cancer-News][img]https://www.oncologytube.com/videos/_YPTuniqid_5f49802789df97.69164865.jpg?1598652495[/img]Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what other cancers are you planning to target with SYD985 - Mar...[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Description:

Marco Timmers, Ph.D., CEO - Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs

https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/

Up Next Autoplay

>